Hardy Reed LLC Acquires 140 Shares of Johnson & Johnson (NYSE:JNJ)

Hardy Reed LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,413 shares of the company’s stock after buying an additional 140 shares during the quarter. Hardy Reed LLC’s holdings in Johnson & Johnson were worth $2,012,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. RBO & Co. LLC boosted its position in shares of Johnson & Johnson by 0.8% during the third quarter. RBO & Co. LLC now owns 211,920 shares of the company’s stock valued at $34,344,000 after buying an additional 1,782 shares during the last quarter. Townsquare Capital LLC lifted its stake in Johnson & Johnson by 12.9% during the 3rd quarter. Townsquare Capital LLC now owns 123,812 shares of the company’s stock valued at $20,065,000 after acquiring an additional 14,185 shares in the last quarter. Transamerica Financial Advisors Inc. boosted its holdings in Johnson & Johnson by 178.9% during the 3rd quarter. Transamerica Financial Advisors Inc. now owns 10,458 shares of the company’s stock worth $1,695,000 after acquiring an additional 6,708 shares during the last quarter. Shum Financial Group Inc. purchased a new stake in shares of Johnson & Johnson in the third quarter valued at about $2,305,000. Finally, Avestar Capital LLC lifted its position in shares of Johnson & Johnson by 19.2% during the third quarter. Avestar Capital LLC now owns 13,090 shares of the company’s stock valued at $2,121,000 after purchasing an additional 2,110 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $154.51 on Wednesday. The firm has a market capitalization of $372.00 billion, a P/E ratio of 22.36, a PEG ratio of 2.77 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a fifty day moving average price of $159.73 and a 200-day moving average price of $156.39.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the company earned $2.66 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.21%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada upped their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.94.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.